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Abstract
The Global Network’s Antenatal Corticosteroids Trial (ACT), was a multi-country, cluster-randomized trial to improve
appropriate use of antenatal corticosteroids (ACS) in low-resource settings in low-middle income countries (LMIC).
ACT substantially increased ACS use in the intervention clusters, but the intervention failed to show benefit in the
targeted < 5th percentile birth weight infants and was associated with increased neonatal mortality and stillbirth in
the overall population. In this issue are six papers which are secondary analyses related to ACT that explore
potential reasons for the increase in adverse outcomes overall, as well as site differences in outcomes. The
African sites appeared to have increased neonatal mortality in the intervention clusters while the Guatemalan
site had a significant reduction in neonatal mortality, perhaps related to a combination of ACS and improving
obstetric care in the intervention clusters. Maternal and neonatal infections were increased in the intervention
clusters across all sites and increased infections are a possible partial explanation for the increase in neonatal
mortality and stillbirth in the intervention clusters, especially in the African sites. The analyses presented here
provide guidance for future ACS trials in LMIC. These include having accurate gestational age dating of study
subjects and having care givers who can diagnose conditions leading to preterm birth and predict which
women likely will deliver in the next 7 days. All study subjects should be followed through delivery and the
neonatal period, regardless of when they deliver. Clearly defined measures of maternal and neonatal infection
should be utilized. Trials in low income country facilities including clinics and those without newborn intensive care
seem to be of the highest priority.
Background
Preterm birth is now considered the most common
cause of neonatal mortality worldwide [1]. To reduce
neonatal mortality and morbidity associated with pre-
term birth, antenatal corticosteroids (ACS) are com-
monly used in women at risk to deliver preterm in
both high-income countries (HIC) and middle-income
countries (MIC) [2, 3]. To date, the efficacy of ACS
has been studied in HIC and some MIC settings in
26 randomized trials and summarized in numerous
meta-analyses [4–9]. Overall, when ACS are given to
the mother in those settings between 24 and 34 weeks
gestation, at 12–24 hours prior to delivery and the
delivery occurs within 7 days, there is a 31 % reduc-
tion in the neonatal mortality rate (NMR) as a result
of reduced risks of respiratory distress syndrome, in-
traventricular hemorrhage, necrotizing enterocolitis,
and other pleotropic effects that improve infant out-
comes [4, 6, 7]. Although the ACS are generally con-
sidered safe for the mother and newborn, a slight
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increase risk in neonatal mortality among women
who receive ACS and delivered at term was reported
in two trials [6]. Moreover, one meta-analysis of ran-
domized trials of infants whose mothers received ACS
but delivered more than one week after ACS adminis-
tration showed higher perinatal mortality rates and
more perinatal infections than the controls [9].
To address the lack of information on the impact
of ACS use in low and middle income countries
(LMIC), the NICHD Global Network designed a clus-
ter randomized trial, the Antenatal Corticosteroids
Trial (ACT), in Zambia, Kenya, Pakistan, India,
Argentina and Guatemala to assess the effects of an
intervention to increase use of ACS through training
birth attendants to identify pregnant women at high
risk of preterm birth and providing ACS kits [10].
Even though ACS use increased from about 10 % in
the control clusters to 46 % in the intervention clus-
ters, not only did NMR not decrease among low birth
weight (<5th percentile) infants as hypothesized, but
the NMR and stillbirth rates also increased overall, an
unanticipated finding [11].
We performed a series of secondary analyses in order
to better understand the failure of the ACT interven-
tion to reduce neonatal mortality in the target group
and the increased overall neonatal mortality and still-
birth rates. We also reviewed prior research on ACS,
and held a meeting with experts from the National In-
stitutes of Health, World Health Organization, Bill and
Melinda Gates Foundation, USAID and other investiga-
tors studying corticosteroids to present the secondary
ACT findings. Here we summarize the secondary analyses.
Secondary analyses
A series of secondary analyses further explored the rea-
sons for the unexpected overall increases in neonatal
mortality and stillbirth, the possible impact of maternal
and newborn infection on these outcomes, and the site
differences [12–16]. We include a case study from
Guatemala, where a significant improvement in neonatal
mortality was observed in the target group. Furthermore,
we examined baseline rates of neonatal infection across
Global Network sites [17]. The analyses suggest that a
potential explanation for the increase in both neonatal
mortality and stillbirth in the intervention clusters was
an increase in neonatal and maternal infections. There
were also worse outcomes associated with the interven-
tion in the African sites but an apparent reduction in
neonatal mortality among the target < 5th percentile
birth weight infants in the Guatemala site. These results
presented in this journal suggest that the decrease in
neonatal mortality in Guatemala may have been related
to the combination of improved medical care plus ACS
use. Across all sites, the increase in neonatal mortality
and stillbirth in the treatment clusters overall may have
been related to increased maternal and neonatal infec-
tion associated with the intervention. However, no de-
finitive reasons for the increases in either neonatal
mortality or stillbirth have been identified. Equally as
important, we emphasize that there was no decrease in
neonatal mortality in the targeted <5th percentile infants.
These hypothesis-generating secondary analyses suggest
that future research should focus on neonatal and ma-
ternal infectious outcomes as well as the importance of
collecting trial outcomes through delivery and the neo-
natal period among all women and their fetuses and ne-
onates who receive ACS and their controls.
ACT in the context of other ACS research
A cautionary observation about ACS research is that
most of the trials to establish efficacy were conducted
between the 1970’s and the early 1990’s, more than
25 years ago. As time elapses from original research and
practice, there is increased likelihood for the results to
have changed [18, 19]. Thus, careful assessment of older
studies in the context of new research is warranted.
The ACT study had several characteristics which dis-
tinguished it from the individually randomized trials
performed in HICs and MICs from 1972 through the
2000’s. First, the initial trials were conducted in hospi-
tals with good obstetric and neonatal care, while ACT
included deliveries within defined geographic areas
among an entire population, whether deliveries were in
the homes, clinics or lower level hospitals. Few, if any,
of the hospital births in ACT were in facilities that
approached the level of care available for the previous
trials. Second, because ultrasound was rarely available
and the gestational age dating unreliable, the ACT
study used a surrogate measure for preterm delivery,
births at <5th percentile of birth weight adjusted for the
population at each participating site. Third, even
though the ACT supervisors trained health workers on
the conditions associated with preterm birth including
preterm labor, membrane rupture, significant bleeding
and preeclampsia that prompted ACS administration,
these providers – often community health workers or
traditional birth attendants – generally had little experi-
ence in diagnosing those conditions. Fourth, at some of
the ACT sites, the women were more likely than
women in the prior trials to carry various infectious or-
ganisms and have poor nutritional status. Women and
newborns in the entire ACT population for both arms
of the trial were followed to 42 days after birth and thus
neonatal outcomes were available for the entire popula-
tion of deliveries at each site. Follow-up to this extent
was rarely performed in prior trials. Finally, the ACT
study included nearly 100,000 deliveries in the clusters
of which more than 6,000 mothers in the intervention
McClure et al. Reproductive Health  (2016) 13:61 Page 2 of 4
clusters received ACS, while the sum of those enrolled
and randomized in the initial trials of a single course of
ACS was approximately 4,000. The small but significant
increase in NMR observed in the ACT results would
not have been detected in the smaller previous studies
with lower baseline risks.
Another important strength of ACT was the at-
tempt to collect outcome data on everyone in the
trial whether they were delivered in a hospital or not
through 42 days post-delivery. In reviewing previous
research of ACS, the follow-up of those women and
newborns who delivered outside the expected window
of ACS benefit or outside the preterm period was
often inadequate. In most cases, data were available
only to hospital discharge; outcomes among infants in
the studies after discharge for most ACS research
were usually not available. A subgroup analysis of the
2006 Cochrane review of 18 studies evaluating neo-
natal mortality, found that that only three of the
studies included results at gestational age >36 weeks
[6]. Thus of the 18 trials including near 4,000 women,
we do not know the proportion of women overall
who eventually delivered at term. Interestingly, of the
613 newborns for which this type of data were avail-
able, the neonatal mortality rate was increased 2 to 3
fold. Another review asked the question about out-
comes in women who delivered more than seven days
after receiving ACS [9]. In this meta-analysis, only
seven studies had data to answer this question. In the
analysis limited to those studies, both perinatal mortality
and chorioamnionitis were increased among maternal/in-
fant dyads who received ACS. The ACT results, which
showed a small increase in neonatal mortality and still-
births concentrated in the heavier and more mature in-
fants and fetuses and a possible increase in maternal and
neonatal infections, are consistent with the available re-
sults from individually randomized trials in HIC.
Another difference among trials is the choice of corti-
costeroids - betamethasone or dexamethasone. Several
trials comparing these corticosteroids have shown that
betamethasone may be more efficacious than dexa-
methasone, although in a meta-analyses, differences
were not statistically different [20, 21]. The formulation
of betamethasone phosphate and betamethasone acet-
ate initially used by Liggins and Howie has been more
frequently been used in HIC research [22]. Dexametha-
sone, which is the WHO recommended drug and is
more widely available in LMIC likely due to its stability
and lower cost compared to betamethasone, was used
for ACT [23, 24]. In the meta-analyses, dexamethasone
was associated with maternal infection (although non-
significant) and there may be subtle but important differ-
ences in the effect of these different drugs. The optimal
dose for dexamethasone is unknown [6, 21].
Gaps in research
Given the results from ACT and other trials, it is
clear that a number of important research questions
remain regarding ACS research, especially in low-
resource settings. First, since it is likely that only
pregnancies at risk of preterm delivery are likely to
benefit from ACS, it is crucial to have accurate gesta-
tional age dating in order to enroll subjects within
the desired treatment window. Second, it is also es-
sential to have qualified obstetric providers make the
judgment about which patients are likely to deliver
within the one week period of maximal benefit. Third,
it is necessary to follow each enrolled patient and her
newborn to delivery and for at least 28 days after
birth. Following only those who deliver within the
preterm period or to hospital discharge will not pro-
vide a full understanding of the benefits and risks of
ACS. Finally, one must determine the appropriate
level of care where research is warranted. A trial con-
ducted in a LMIC probably should not randomize
women delivering in facilities similar to those in
which the high-income studies were undertaken, since
there is little reason to believe that in those facilities,
benefits would not occur. Also, given the difficulties
the ACT teams encountered in getting ACS to the
appropriate women who have their suspected preterm
births at home as well as the necessary follow-up
care, we do not believe that another ACS trial involv-
ing home births is appropriate at this time.
There is a large movement throughout LMIC to shift
births into clinics and lower level or district hospitals,
generally without newborn special care [25]. Therefore,
we believe the most important question to answer right
now is whether ACS can be given to the appropriate
women and whether ACS reduce neonatal mortality in
those settings [26]. Any study done on ACS in low-
income settings must evaluate the mothers, fetuses and
newborns for infection to evaluate the safety of the
intervention. In summary, research questions that may
inform future programs to roll-out ACS in these settings
include the following:
1) Gestational age assessment: What is the best way
to determine gestational age and which outcomes
associated with ACS use are impacted in different
gestational age windows?
2) Risk population: Which factors predict preterm
delivery in LMIC and what is the best way to
ensure that providers can identify signs of risk?
3) Obstetric and neonatal care: What is the impact of
ACS when administered to women delivering at
different levels of obstetric and neonatal care?
4) Infectious outcomes: What maternal and newborn
infectious outcomes are associated with ACS?
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Conclusions
The ACT findings have important programmatic impli-
cations for many international global health agencies,
foundations and individual countries planning on scaling
up the use of ACS. The lack of benefit in the targeted
neonates and the increased stillbirths and neonatal
deaths overall were unexpected. Our attempts to under-
stand these outcomes in secondary analyses of the ACT
data provided clues but no clear answers. These analyses
do however provide guidance for future ACS trials in
LMIC. These include having gestational age dating of
study subjects and having care givers who can diagnose
conditions leading to preterm birth and predict with
some degree of accuracy which women are likely to
deliver within the next seven days. Finally, all subjects
entered into the trial should be followed through deliv-
ery and the neonatal period, regardless of whether they
deliver preterm or at term. Clearly defined measures of
maternal and neonatal infection should be determined
prior to any study and be included as an outcome. Trials
in low income country facilities including clinics and
those without newborn intensive care seem to be of the
highest priority.
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